Does CareFirst BlueCross BlueShield Cover Dupixent?

What Is Dupixent and Why Does Coverage Get Complicated?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks IL-4 and IL-13 signaling through the shared IL-4 receptor alpha subunit. The FDA first approved it in March 2017 for adults with moderate-to-severe atopic dermatitis inadequately controlled by topical therapies [1]. Since then, the agency has expanded the label to cover uncontrolled moderate-to-severe asthma (2018), chronic rhinosinusitis with nasal polyps (2019), eosinophilic esophagitis in patients 12 and older (2022), prurigo nodularis (2022), and, most recently, eosinophilic COPD in adults (2024) [2].

Because Dupixent carries a wholesale acquisition cost of roughly $37,000 per year and competes in a specialty biologics class, every major commercial insurer, including CareFirst BlueCross BlueShield, places it on a high-cost specialty tier and routes it through a managed specialty pharmacy with a prior-authorization gate.

Why IL-4/IL-13 Blockade Is Clinically Significant

The SOLO 1 and SOLO 2 trials (combined N=1,379) demonstrated that dupilumab 300 mg every two weeks produced an IGA 0/1 ("clear or almost clear") response in 38% of adults with moderate-to-severe atopic dermatitis versus 10% on placebo at 16 weeks (P<0.001) [3]. That clinical magnitude is why dermatologists and allergists push hard for coverage even when plans initially deny.

The Specialty Pharmacy Channel

CareFirst routes Dupixent through contracted specialty pharmacies, most commonly CVS Specialty, Walgreens Specialty, or Biologics by McKesson, depending on plan type. Your prescriber must send the prescription directly to one of these pharmacies; a retail or mail-order prescription will be rejected at adjudication.

CareFirst Formulary Placement and Tier Structure

CareFirst BlueChoice, CareFirst BCBS Federal Employee Program (FEP), and CareFirst Medicare Advantage each maintain separate formularies, so "covered" means different things depending on which product you hold.

Commercial Plans (BlueChoice HMO, PPO, and Tiered Networks)

On standard CareFirst commercial plans, Dupixent sits on the specialty tier (tier 4 or tier 5). Member cost-sharing at this tier typically ranges from 25% to 40% coinsurance after the deductible is met, capped at the plan's out-of-pocket maximum. For a $37,000/year drug, that means a member could owe $9,250 to $14,800 per year before hitting the cap.

The American Academy of Dermatology guidelines classify dupilumab as a first-line biologic option for moderate-to-severe atopic dermatitis in patients who have failed topical therapy [4]. CareFirst's clinical coverage criteria generally mirror this standard, requiring documented inadequate response to at least one medium-to-high-potency topical corticosteroid over a defined trial period (commonly 4-12 weeks).

Federal Employee Program (FEP)

The CareFirst FEP Blue Focus and FEP Blue Standard plans operate under the Federal Employees Health Benefits Act and publish a separate formulary updated each January. The 2024 FEP formulary lists Dupixent as a "non-preferred specialty" drug with a member cost-share up to $200 per 30-day supply after the deductible, subject to PA requirements. Consult the Office of Personnel Management's annual FEHB brochure (updated each fall) to confirm the current-year figure [5].

Medicare Advantage

CareFirst Medicare Advantage plans place Dupixent in Part D specialty tier 5. CMS regulations cap specialty-tier beneficiary cost-sharing at 25% during the initial coverage phase under the Inflation Reduction Act redesign effective 2025, with a $2,000 annual out-of-pocket cap for Part D drugs [6]. This represents a meaningful reduction compared to prior years for Medicare members.

Prior Authorization: What CareFirst Requires

Prior authorization is a formal clinical review process in which CareFirst's pharmacy benefit manager evaluates whether the requested drug is medically necessary under the plan's criteria. For Dupixent, that review almost always requires the following documentation.

Diagnosis Confirmation

The prescribing clinician must document an ICD-10-CM code consistent with an FDA-approved indication: L20.9 (atopic dermatitis, unspecified), J45.51 (severe persistent asthma with acute exacerbation), K20.0 (eosinophilic esophagitis), or another applicable code. The diagnosis must be supported by clinical notes from a dermatologist, allergist, or relevant specialist.

Step Therapy Documentation

CareFirst generally requires evidence of a trial and failure of conventional agents before approving a biologic. For atopic dermatitis, this typically means a documented trial of a medium-to-high-potency topical corticosteroid (e.g., triamcinolone 0.1% cream or clobetasol 0.05% cream) for 4-12 weeks. Some plans also require a trial of a topical calcineurin inhibitor (tacrolimus 0.1% ointment) or topical PDE4 inhibitor (crisaborole 2% ointment) prior to dupilumab approval.

Maryland, Virginia, and Washington D.C. (the primary CareFirst service area) each have enacted step therapy override laws requiring insurers to grant an exception when step therapy is clinically inappropriate, when the patient previously tried and failed the required agent, or when the required agent is contraindicated [7].

Clinical Severity Documentation

For atopic dermatitis, CareFirst PA reviewers look for documented disease severity using a validated scale. The Eczema Area and Severity Index (EASI) and the Investigator Global Assessment (IGA) are both acceptable. An EASI score above 21 (moderate-to-severe range) or an IGA of 3-4 typically satisfies the severity threshold.

Lab and Safety Requirements

Dupixent does not require routine lab monitoring per its FDA prescribing information, but CareFirst may ask for a current serum IgE level or eosinophil count when the indication is asthma or EoE. Confirm current lab requirements with the specialty pharmacy at the time of PA submission.

The HealthRX Prior Authorization Readiness Checklist for Dupixent (CareFirst):

1. ICD-10 diagnosis code confirmed by a specialist note dated within 12 months.
2. Documented step therapy trial with dates, agents used, concentrations, and reason for failure (side effects vs. Insufficient response).
3. Validated severity score (EASI, IGA, or ACQ-5 for asthma) recorded in the clinical note.
4. Specialty pharmacy selected from CareFirst's contracted network.
5. NPI number, DEA number, office address, and tax ID of prescribing physician on the PA form.
6. Patient's current insurance ID, group number, and date of birth confirmed against the CareFirst member portal.

How to Submit a Prior Authorization for Dupixent Through CareFirst

The prescribing physician's office, not the patient, submits the PA. The steps below are consistent with CareFirst's commercial PA workflow as of 2025.

Step 1: Verify Benefits First

Call the CareFirst specialty pharmacy benefits line (1-800-544-8703) or log in to the provider portal at provider.carefirst.com to confirm that the patient's specific plan covers Dupixent and to obtain the current PA criteria document for the patient's benefit year.

Step 2: Complete the PA Form

CareFirst accepts PA submissions through its provider portal (NaviNet/Availity), by fax to the specialty pharmacy PA department, or via electronic PA platforms such as CoverMyMeds. The PA form requires the clinical details listed in the checklist above.

Step 3: Respond to Additional Information Requests

CareFirst's PA team may issue a request for additional information (RAI) within 5-10 business days. The physician's office typically has 10 business days to respond; failure to respond within that window may result in a technical denial.

Step 4: Approval, Denial, or Step Therapy Exception

PA decisions for non-urgent requests must be issued within 14 days under Maryland law and within 14-30 days under Virginia and D.C. Law [7]. Urgent requests (where delay would seriously jeopardize health) must be adjudicated within 72 hours.

What to Do If CareFirst Denies Dupixent Coverage

A denial is not the end of the process. Patients and prescribers have several formal recourse options under both federal and state law.

Internal Appeal

Every CareFirst plan must offer at least one level of internal appeal. The denial letter must include the specific clinical criteria used to deny the request, the ICD-10 code involved, and instructions for filing an appeal. An appeal must typically be filed within 180 days of the denial date. The physician should submit a letter of medical necessity that directly addresses the denial rationale, ideally citing published clinical trial data.

The LIBERTY AD CHRONOS trial (N=740, 52 weeks) showed that dupilumab 300 mg every two weeks produced a 65% reduction in EASI score versus 22% on placebo at week 52 (P<0.001), supporting long-term medical necessity arguments [8].

External Independent Review

If the internal appeal fails and the denial involves medical necessity (rather than a plan exclusion), patients in Maryland, Virginia, and D.C. Have the right to request an external independent review by a state-approved independent review organization. CareFirst must abide by the independent reviewer's decision. Contact the Maryland Insurance Administration (410-468-2000), Virginia Bureau of Insurance (877-310-6560), or D.C. Department of Insurance (202-727-8000) to initiate this process.

Step Therapy Override Request

Under Maryland's step therapy law (Md. Code Ann., Ins. § 15-1533) and Virginia's step therapy law (Va. Code Ann. § 38.2-3407.15), a prescriber may request an exception to step therapy if [7]:

• The required step drug is contraindicated or would cause an adverse reaction.
• The patient previously tried the required drug and it was clinically ineffective or caused an adverse reaction.
• The required drug is not in the patient's best interest based on clinical evidence.

CareFirst must respond to a step therapy override request within 72 hours (urgent) or 14 days (standard).

The Cost Reality: What Members Actually Pay

Even with coverage approved, out-of-pocket costs for a specialty biologic can be substantial. Several programs exist to reduce these costs.

Sanofi Dupixent MyWay Copay Card

Commercially insured patients who are not enrolled in a government-funded health program (Medicare, Medicaid, TRICARE) may qualify for the Dupixent MyWay copay assistance program. As of 2024, eligible patients may pay as little as $0 per month, with Sanofi covering up to $13,000 per year in copay costs. Enrollment is available at dupixent.com/myway or by calling 1-844-DUPIXENT (1-844-387-4936) [9].

Patient Assistance Program (PAP)

Uninsured or underinsured patients who meet income criteria (generally below 600% of the federal poverty level) may qualify for free Dupixent through Sanofi's patient assistance program. The prescriber must complete a PAP enrollment form along with proof of income documentation.

State Pharmaceutical Assistance Programs

Maryland's Pharmacy Assistance Program (MPAP) and the D.C. Pharmaceutical Assistance Program (DCPAP) offer supplemental cost-sharing support for qualifying residents. Income thresholds and benefit structures change annually; confirm current eligibility at the respective state health department websites.

Out-of-Pocket Maximum Protections

Under the Affordable Care Act, all non-grandfathered individual and small-group plans must cap annual out-of-pocket costs. For 2025, the ACA out-of-pocket maximum is $9,200 for an individual and $18,400 for a family [10]. Once a CareFirst member reaches this cap, Dupixent costs $0 for the remainder of the plan year.

Dupixent's FDA-Approved Indications: Does Your Diagnosis Qualify?

Coverage decisions hinge directly on whether the prescribed use matches an FDA-approved indication. Off-label use of Dupixent is generally not covered by CareFirst.

Atopic Dermatitis

FDA approval covers moderate-to-severe atopic dermatitis in patients 6 months and older whose disease is not adequately controlled with topical therapies or when those therapies are not advisable [1]. This is the most common reason Dupixent is prescribed and the indication with the most strong clinical trial data.

The CAFE trial (N=325) evaluated dupilumab in patients with moderate-to-severe atopic dermatitis who had failed or were contraindicated to cyclosporine, demonstrating a 59.1% EASI-75 response rate versus 29.8% on placebo at week 16 (P<0.001) [11]. This trial is particularly useful in supporting PA approvals when step therapy requirements include a systemic immunosuppressant.

Asthma

Dupixent is approved as an add-on maintenance treatment for patients 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or oral corticosteroid-dependent asthma [2]. CareFirst typically requires a baseline blood eosinophil count of at least 150 cells/microliter, an ACQ-5 score of 1.5 or higher, and documentation of at least one asthma exacerbation in the prior 12 months.

The QUEST trial (N=1,902) showed that dupilumab 200 mg every two weeks reduced annualized severe exacerbation rates by 47.7% in the overall population versus placebo (P<0.001), with even greater benefit in patients with baseline eosinophils of at least 300 cells/microliter (65.8% reduction) [12].

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Approved as add-on maintenance therapy for adults with inadequately controlled CRSwNP, with documented bilateral nasal polyp burden on endoscopy or CT imaging. CareFirst typically requires prior use of intranasal corticosteroids and documentation of sinonasal surgery history or documented nasal polyp score.

Eosinophilic Esophagitis (EoE)

Approved for patients 12 years and older weighing at least 40 kg, requiring documentation of esophageal eosinophilia confirmed by biopsy (at least 15 eosinophils per high-power field) and inadequate response to a proton pump inhibitor trial [13].

Prurigo Nodularis

Approved for adults with prurigo nodularis in 2022. CareFirst PA criteria for this indication typically require documented nodular lesions with chronic pruritus and prior trial of a topical agent or antihistamine.

Eosinophilic COPD

The most recent indication (2024) covers adults with inadequately controlled COPD characterized by eosinophilic inflammation (blood eosinophils at least 300 cells/microliter). This indication is new, and coverage criteria across all plans, including CareFirst, are still being finalized as of mid-2025.

Renewals, Continuations, and Long-Term Coverage

PA approvals for Dupixent are not permanent. CareFirst typically approves Dupixent for 12 months at a time, after which a PA renewal is required.

What Renewal Requires

Renewal PA submissions must document a clinical response to dupilumab. CareFirst reviewers look for a meaningful reduction in disease severity scores (e.g., at least a 50% reduction in EASI for atopic dermatitis, or documented reduction in asthma exacerbation frequency). The treating physician's office should track and record these outcomes in the chart beginning at the first injection visit.

Switching Between Plans

If a patient changes CareFirst plan types (e.g., from BlueChoice HMO to a PPO during open enrollment), a new PA must be submitted even if Dupixent was previously approved under the prior plan. Benefits do not automatically transfer across plan types within the same insurer.

Prescriber Tips for Getting Dupixent Approved on the First Submission

Denials are most commonly triggered by incomplete documentation, missing step therapy records, or inadequate severity documentation. The following practices significantly improve first-pass approval rates.

Use a Validated Severity Tool at Every Visit

Record an IGA or EASI score at baseline and at every follow-up visit. CareFirst reviewers are trained to look for these scores. A chart note that says "severe eczema" without a numeric score is far weaker than one that says "EASI 28.4 at today's visit despite 8 weeks of clobetasol 0.05% cream twice daily."

Write a Detailed Letter of Medical Necessity

A letter of medical necessity (LMN) that directly quotes the applicable clinical trial data, references the AAD guidelines [4], and addresses each of CareFirst's stated criteria by name is substantially more persuasive than a generic form letter. Many specialty pharmacies provide LMN templates tailored to specific payer criteria.

Enroll the Patient in Dupixent MyWay Before the First Injection

Enrolling patients in the Sanofi copay assistance program before the first dose is dispensed avoids a gap where the patient might owe the full specialty-tier cost-share while awaiting copay card processing [9].

Document Every Communication With CareFirst in the Chart

Note the date, time, CareFirst representative name, and call reference number for every phone interaction. This documentation is essential if the case proceeds to an appeal or external review.